BioMedNewsBreaks

WednesdayApr 15, 2026 12:21 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Advancing Multi-Platform Healthcare Strategy

Earth Science Tech (OTC: ETST), a strategic holding company, was featured in a recent article that discussed its strives to build value by acquiring and actively managing businesses. The publication reads, “Earth Science Tech takes an approach that prioritizes capital discipline, execution, and long-term value creation across the platforms it operates, while focusing on scaling businesses that can grow sustainably and increase shareholder value. The wholly owned and majority-owned subsidies that the company operates include: Mister Meds LLC: A compounding pharmacy that delivers personalized wellness plans and dedicated support to patients across the USA… RxCompoundStore.com LLC: Another compounding pharmacy that’s authorized…

Continue Reading

WednesdayApr 15, 2026 12:10 pm

BioMedNewsBreaks — Polyrizon Ltd. (NASDAQ: PLRZ) Closes $3.5 Million Registered Direct Offering and Concurrent Private Placement 

Polyrizon (NASDAQ: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, announced the closing of its previously announced registered direct offering and concurrent private placement with a single institutional investor, generating approximately $3.5 million in gross proceeds. The transactions included the sale of 388,888 units or pre-funded units at a combined price of $9.00 per unit, consisting of ordinary shares or pre-funded warrants and common warrants, with additional pre-funded and common warrants issued in the private placement, as the company plans to use proceeds for working capital and general corporate purposes, while Aegis Capital Corp. acted as exclusive placement agent. To view…

Continue Reading

WednesdayApr 15, 2026 9:59 am

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Engages Venture Liquidity Providers for Market-Making Services 

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.  MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), a biotechnology company focused on AI-driven voice analytics for drug and alcohol intoxication detection, announced it has appointed Venture Liquidity Providers (VLP), subject to regulatory and final approvals, to provide market-making services aimed at maintaining an orderly trading market for its common shares. The service will be conducted through W.D. Latimer Co. Ltd. in compliance with Canadian Securities Exchange policies, with MindBio agreeing to pay $5,000 per month over a 12-month term, which may be terminated at any time, while both parties operate at arm’s length and…

Continue Reading

WednesdayApr 15, 2026 9:45 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications

NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression and PTSD, announced the formation of NRx Defense Systems Inc., a Florida-based research and development subsidiary dedicated to advancing combined neuroplastic treatments using D-cycloserine and transcranial magnetic stimulation supported by robotic-enabled neuronavigation. The subsidiary will be led by Dr. Dennis McBride, with support from Chief Medical Innovation Officer Dr. Joshua Brown, and aims to pursue non-dilutive government and institutional funding while developing deployable solutions for military and first responder use, including a prototype in partnership with Zeta Surgical Inc. expected to be unveiled at the Clinical TMS…

Continue Reading

WednesdayApr 15, 2026 9:15 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Launches Proposed Public Offering to Support Commercialization and AI Initiatives

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it is commencing an underwritten public offering of shares of its common stock or common stock equivalents, with all securities to be offered by the company and the final size and terms subject to market conditions. The company said it intends to use net proceeds from the offering to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection initiatives, enhance its AI capabilities and support working capital and general corporate purposes, with Titan Partners, a division of…

Continue Reading

TuesdayApr 14, 2026 1:31 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Showcased for Smarter Path to Drug Development

Soligenix (NASDAQ: SNGX) was featured in a recent article that discussed its positioning in a landscape where modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism can unlock treatments for multiple diseases. “Soligenix exemplifies this strategy through its use of synthetic hypericin across two distinct dermatologic indications, illustrating how platform science can streamline development and expand clinical impact,” the publication reads. “Platform-based drug development has gained traction across the biotechnology industry because of its efficiency and risk management advantages. In drug development, platform technology is a foundational technology or system that serves as a base for the development…

Continue Reading

MondayApr 13, 2026 11:58 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints First Chief Commercial Officer Ahead of Ketamine Launch 

NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression, PTSD and related conditions, announced the appointment of Glenn Tyson as its first Chief Commercial Officer as the company prepares for anticipated approval of its Abbreviated New Drug Application for a preservative-free ketamine product. Tyson brings more than 25 years of commercialization and sales experience, including senior leadership roles at GSK and Indivior, where he led the successful launch of SUBLOCADE(R), and will oversee the buildout of market access, distribution, sales and marketing capabilities to support upcoming product launches and the company’s broader psychiatry pipeline, including NRX-100 and NRX-101. To…

Continue Reading

MondayApr 13, 2026 11:28 am

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company advancing cancer treatments, announced preliminary results from a clinical trial evaluating its proprietary compound LB-100 in combination with dostarlimab at the 2026 Society of Gynecologic Oncology conference in San Juan, Puerto Rico. Interim data from 20 evaluable patients showed a 40% disease control rate and encouraging survival trends with an acceptable safety profile, supporting continued enrollment of an expanded cohort as the company investigates the combination’s potential to enhance immunotherapy response in ovarian clear cell carcinoma. To view the full press release, visit https://ibn.fm/alcex About LIXTE Biotechnology Holdings, Inc. LIXTE Biotechnology Holdings, Inc. is a clinical-stage…

Continue Reading

MondayApr 13, 2026 9:40 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Develops Intox Collect(TM) to Scale AI Voice-Based Intoxication Detection

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) a biotechnology company focused on AI-driven voice analytics for intoxication detection, announced the completion of its Intox Collect(TM) technology, enabling rapid scaling of data collection and analysis across a wide range of substances using voice and facial recognition. The platform enhances the company’s ability to train its AI model, which leverages more than 50 million data points to predict drug and alcohol intoxication through voice with high accuracy, while supporting expansion into regulated industries such as…

Continue Reading

MondayApr 13, 2026 9:30 am

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Doses First Patient in Phase IIa Trial of Concussion Treatment

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company focused on brain-targeted therapeutics, announced that the first patient has been dosed in its Phase IIa clinical trial evaluating ONP-002 for concussion and mild traumatic brain injury at Mackay Hospital in Australia, shortly after site activation on March 31, 2026. The milestone follows regulatory approval and highlights progress in advancing a first-in-class intranasal neurosteroid designed to address underlying brain injury mechanisms, as the company expands trial sites and targets a large unmet need in a condition with no FDA-approved pharmacological treatments. To view the full press release, visit https://ibn.fm/85CHs About Oragenics, Inc.…

Continue Reading